首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Influence of intravenously administered ciprofloxacin on aerobic intestinal microflora and fecal drug levels when administered simultaneously with sucralfate.
【2h】

Influence of intravenously administered ciprofloxacin on aerobic intestinal microflora and fecal drug levels when administered simultaneously with sucralfate.

机译:与硫糖铝同时给药时静脉注射环丙沙星对有氧肠道菌群和粪便药物水平的影响。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Ciprofloxacin, when given intravenously (i.v.), is secreted in significant amounts via the mucosa into the intestinal lumen. Sucralfate inhibits the antimicrobial activity of ciprofloxacin. The effect of combined therapy on the intestinal flora was investigated in 16 healthy volunteers. They were randomly assigned to two groups. Group A received 2 g of sucralfate orally three times a day for 7 days and 400 mg of ciprofloxacin i.v. twice a day (b.i.d.) starting 3 days after the sucralfate administration began. Group B was given only 400 mg of ciprofloxacin i.v. b.i.d. for 4 days. A total of 9 stool samples were collected from each subject beginning the week before ciprofloxacin was administered and on days -1, 1, 2, 3, 4, 7, 9, and 10 or 11 after commencement of the infusion period. The aerobic fecal flora was determined by standard microbiological methods. Measurements of fecal ciprofloxacin levels were based on high-performance liquid chromatography. Counts of bacteria of the family Enterobacteriaceae decreased in all subjects and were below 10(2) CFU/g in eight of eight subjects (group A) and six of eight subjects (group B) on day 4, but they returned to normal in all but one subject (group A) 10 days after the last infusion. The decreases in levels of bacteria of the family Enterobacteriaceae were not significantly different in groups A and B (Kaplan-Meier test). Staphylococci and nonfermenters responded variably, enterococci and lactobacilli remained unchanged, and candida levels increased transiently in four subjects (two in each group). Maximum fecal drug levels ranged from 251 to 811 microg/g. No significant difference could be found between the two groups. The i.v. application of ciprofloxacin eliminates intestinal bacteria of the family Enterobacteriaceae in a rapid and selective manner. This effect is not affected by simultaneous oral application of sucralfate.
机译:环丙沙星静脉注射(i.v.)时,会通过粘膜大量分泌到肠腔中。硫糖铝抑制环丙沙星的抗菌活性。在16名健康志愿者中研究了联合治疗对肠道菌群的影响。他们被随机分为两组。 A组每天口服两次硫糖铝,共7天,每天3次,口服环丙沙星400毫克。硫糖铝开始给药后第3天开始,每天两次(公元前)。 B组仅静脉内给予400mg环丙沙星。出价。 4天。从开始服用环丙沙星的一周开始以及在输液期开始后的第-1、1、2、3、4、7、9和10或11天,从每个受试者中总共收集了9个粪便样品。通过标准的微生物学方法测定有氧粪便菌群。粪便环丙沙星水平的测定基于高效液相色谱法。在第4天,所有受试者的肠杆菌科细菌计数均下降,并且在8名受试者(A组)中的8名受试者和8名受试者(B组)中的6名(B组)中低于10(2)CFU / g,但在所有受试者中它们均恢复正常但最后一次输液后10天有一名受试者(A组)。肠杆菌科细菌水平的降低在A组和B组中无显着差异(Kaplan-Meier检验)。葡萄球菌和非发酵菌的反应各不相同,肠球菌和乳杆菌保持不变,四名受试者(每组两名)的念珠菌水平短暂升高。最大粪便药物水平范围从251至811微克/克。两组之间没有发现显着差异。 i.v.环丙沙星的应用可以快速,选择性地消除肠杆菌科的肠道细菌。同时口服硫糖铝不影响该效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号